{"id":1862,"date":"2022-09-05T17:26:00","date_gmt":"2022-09-05T16:26:00","guid":{"rendered":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/?p=1862"},"modified":"2026-01-26T15:02:01","modified_gmt":"2026-01-26T15:02:01","slug":"amphista-therapeutics-opens-cambridges-granta-park-research-facility","status":"publish","type":"post","link":"https:\/\/sites.dundee.ac.uk\/alessio-ciulli\/2022\/09\/05\/amphista-therapeutics-opens-cambridges-granta-park-research-facility\/","title":{"rendered":"Amphista therapeutics opens Cambridge’s Granta Park research facility"},"content":{"rendered":"

Spinout named a \u2018Fierce 15\u2019 Biotech Companies of 2022<\/h2>\n
\n
\"Cutting<\/figure>\n<\/div>\n
\n
\"Celebrating<\/figure>\n
\"Party<\/figure>\n
\"Speech<\/figure>\n<\/div>\n
\n
\"Group<\/figure>\n<\/div>\n

University of Dundee spinout Amphista Therapeutics has been designated as one of the world\u2019s most promising biotechnology companies.<\/p>\n

University of Dundee spinout Amphista Therapeutics has been designated as one of the world\u2019s most promising biotechnology companies.<\/p>\n

Amphista, a leader in next generation targeted protein degradation (TPD), was named as one of 2022\u2019s \u2018Fierce 15\u2019 biotechnology companies by the prestigious industry news outlet Fierce Biotech.<\/p>\n

Amphista\u2019s mission is to unlock the full therapeutic potential of TPD, a revolutionary new approach to drug discovery, by harnessing the body\u2019s natural processes to degrade and remove disease-causing proteins selectively and efficiently. The company is a spinout from the lab of\u00a0Professor Alessio Ciulli<\/a>\u00a0at the University\u2019s\u00a0School of Life Sciences<\/a>.<\/p>\n

Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. The Fierce 15 celebrates the spirit of being \u2018fierce\u2019 \u2013 championing innovation and creativity, even in the face of intense competition.\u00a0<\/p>\n

Nicki Thompson, CEO of Amphista, said \u201cWe are delighted to be selected as a \u2018Fierce 15\u2019 company in a year where we have made outstanding progress in advancing our proprietary Eclipsys\u2122 platform and therapeutic portfolio and in expansion of our world-leading team.\u00a0<\/p>\n

\u201cThis also comes in a year where our technology has been further recognised and validated by our strategic collaborations with global pharmaceutical companies Merck Healthcare, a division of Merck, and Bristol Myers Squibb worth more than $2 billion. We remain dedicated to advancing our ground-breaking science with the potential to open up this exciting modality by delivering medicines to patients across a wider range of diseases.\u201d<\/p>\n

TPD exploits the body\u2019s own cellular waste disposal system to destroy disease-causing proteins, rather than inhibiting their function. This new approach provides hope of treating diseases previously thought to be undruggable and is applicable to diverse areas including oncology, dermatology, immunology, respiratory and central nervous system diseases.<\/p>\n

Degrading rather than inhibiting a target protein offers several advantages such as better drug response at lower doses as well as reduced side effects and disease resistance.<\/p>\n

Amphista\u2019s technology is specifically designed to develop next generation TPD therapeutics based on mechanistic insights and novel chemistry approaches that enable the company to develop novel protein degrading therapeutics with superior levels of efficacy and broad therapeutic applicability.<\/p>\n

Dundee is a world leader in TPD, with its new\u00a0Centre for Targeted Protein Degradation<\/a>\u00a0helping to bolster this position further by building on the work of Professor Ciulli and other scientists based at the University.<\/p>\n

Notes to editors<\/p>\n

About Fierce Biotech<\/p>\n

Fierce Biotech is the biotech industry\u2019s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 450,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day\u2019s top stories. Signup is free at\u00a0www.fiercebiotech.com\/signup<\/a>.<\/p>\n

About Amphista Therapeutics
Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD) that address the challenges faced by earlier stage TPD research and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli\u2019s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.<\/p>\n

For more information, please visit:\u00a0https:\/\/amphista.com\/<\/a><\/p>\n

Related links:<\/p>\n